Recent news on MS: natalizumab is beneficial, stem cell transplantation is not, and the differentiation of neuromyelitis optica and MS is complex

Author： Strupp Michael  

Publisher： Springer Publishing Company

ISSN： 0340-5354

Source： Journal of Neurology, Vol.254, Iss.6, 2007-06, pp. : 820-822

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Natalizumab and the development of extensive brain lesions in neuromyelitis optica

By Juryńczyk Maciej   Zaleski Krzysztof   Selmaj Krzysztof  

Journal of Neurology, Vol. 260, Iss. 7, 2013-07 ,pp. : 1919-1921

Springer Publishing Company

Access to resources Recommend Favorite

Is haematopoietic stem cell transplantation a treatment option for severe MS or not?

By Martin Roland  

Brain, Vol. 130, Iss. 5, 2007-05 ,pp. : 1181-1182

Oxford University Press

Access to resources Recommend Favorite

The spectrum of neuromyelitis optica: a case of NMO with extensive brain stem involvement

By Vendrame Martina   Azizi S. Ausim  

Neurological Research, Vol. 29, Iss. 1, 2007-01 ,pp. : 32-35

Maney Publishing

Access to resources Recommend Favorite

Humoral immune response to influenza vaccine in natalizumab-treated MS patients

By Vågberg Mattias   Kumlin Urban   Svenningsson Anders  

Neurological Research, Vol. 34, Iss. 7, 2012-09 ,pp. : 730-733

Maney Publishing

Access to resources Recommend Favorite

MOG-IgG in neuromyelitis optica

By Luppe Sebastian   Robertson Neil  

Journal of Neurology, Vol. 261, Iss. 3, 2014-03 ,pp. : 640-642

Springer Publishing Company

Access to resources Recommend Favorite